NasdaqGS:EXELBiotechs
Exelixis (EXEL) And The Valuation Case For Its Cabometyx Growth Story
Exelixis stock performance snapshot after recent trading
Exelixis (EXEL) stock recently closed at US$54.55, with short term returns that have shifted over the past week and month. Investors may be reassessing the oncology company’s value score of 5 and intrinsic discount of 70%.
See our latest analysis for Exelixis.
Over the past year, Exelixis has combined short term share price momentum with stronger long term gains, with a year to date share price return of 25.17% and a 1 year total...